Mitogen-activated protein kinase kinase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 27: Line 27:
</StructureSection>
</StructureSection>
[[Mitogen-activated protein kinase kinase 3D structures]]
[[Mitogen-activated protein kinase kinase 3D structures]]
-
== 3D Structures of Mitogen-activated protein kinase kinase ==
 
-
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
 
-
{{#tree:id=OrganizedByTopic|openlevels=0|
 
- 
-
*MAP2K1; Domains – PB1 2-124; kinase 62-393
 
- 
-
**[[3mbl]], [[3e8n]], [[3dy7]], [[3eqb]], [[2p55]], [[4ark]] – hMAP2K1 kinase domain +MgADP+ligand - human<br />
 
-
**[[3eqc]] – hMAP2K1 kinase domain+ATP-Gs+Mg2P<br />
 
-
**[[3eqd]] - hMAP2K1 kinase domain (mutant)+ATP-Gs+Mg2P<br />
 
-
**[[3eqf]] - hMAP2K1 kinase domain (mutant)+inhibitor+Mg2P<br />
 
-
**[[3eqg]], [[3eqi]] - hMAP2K1 kinase domain (mutant)+ADP+Mg2P+Pd<br />
 
-
**[[3eqh]] - hMAP2K1 kinase domain (mutant)+ADP+Mg2P+inhibitor<br />
 
-
**[[3orn]], [[4lmn]], [[3wig]] - hMAP2K1 kinase domain +MgAMP-PNP +inhibitor<br />
 
-
**[[3sls]] – hMAP2K1 kinase domain (mutant) + Mg + AMPPNP + inhibitor<br />
 
-
**[[4an2]], [[4an3]], [[4an9]], [[4anb]] – hMAP2K1 kinase domain (mutant) + Mg + ACP + inhibitor<br />
 
-
**[[3zls]], [[3zlw]], [[3zlx]], [[3zly]], [[3zm4]] – hMAP2K1 kinase domain + inhibitor<br />
 
-
**[[3os3]], [[3pp1]], [[3v01]], [[3v04]], [[3vvh]] - hMAP2K1 kinase domain + MgATP +inhibitor<br />
 
-
**[[3eqi]] - hMAP2K1 kinase domain (mutant)+ADP+Mg2P+Pd<br />
 
-
**[[3dv3]] - hMAP2K1 kinase domain +inhibitor<br />
 
-
**[[1s9j]] – hMAP2K1 kinase domain +MgATP+ligand<br />
 
-
**[[3w8q]] – hMAP2K1 kinase domain + ATP-γS <br />
 
-
**[[4mne]] – hMAP2K1 kinase domain + Mg + ATP-γS + proto-oncogene B-raf<br />
 
-
**[[6pp9]] – hMAP2K1 kinase domain + Mg + AMPPNP + proto-oncogene B-raf<br />
 
-
**[[6u2g]] – hMAP2K1 kinase domain + Mg + AMPPCP + proto-oncogene B-raf<br />
 
-
**[[6q0j]], [[6q0t]] – hMAP2K1 kinase domain (mutant) + B-raf + 14-3-3 protein ζ – Cryo EM<br />
 
-
**[[1sko]] - hMAP2K1 PB1 domain +P14<br />
 
-
**[[3cpt]] - hMAP2K1 PB1 domain +P14 (mutant)<br />
 
-
**[[1vet]], [[1veu]] - mMAP2K1+P14 - mouse<br />
 
- 
-
*MAP2K2
 
- 
-
**[[1s9i]] – hMAP2K2 kinase domain +MgATP+ligand<br />
 
- 
-
*MAP2K4
 
- 
-
**[[3aln]] - hMAP2K4 kinase domain +AMPPNP<br />
 
-
**[[3alo]] - hMAP2K4 kinase domain + P38 peptide
 
- 
-
*MAP2K5
 
- 
-
**[[2o2v]] – hMAP2K5 PB1 domain + hMAP3K3B PB1 domain<br />
 
-
**[[1wi0]] - mMAP2K5 PB1 domain – NMR<br />
 
- 
-
*MAP2K6
 
- 
-
**[[3vn9]] - hMAP2K6<br />
 
-
**[[3enm]] – hMAP2K6 (mutant)<br />
 
-
**[[3fme]] – hMAP2K6 kinase domain (mutant)<br />
 
- 
-
*MAP2K7 kinase domain 101-421
 
- 
-
**[[6qfl]], [[6qfr]], [[6yfz]], [[6yg1]] – hMAP2K7<br />
 
-
**[[2dyl]], [[6yg0]] – hMAP2K7 (mutant)
 
-
**[[6ib0]], [[6ib2]], [[6qft]], [[6qg4]], [[6qg7]], [[6qho]], [[6qhr]], [[6yg3]], [[6yg4]], [[6yg5]], [[6yg6]], [[6yg7]] – hMAP2K7 + inhibitor<br />
 
-
**[[6yg2]], [[6yz4]] – hMAP2K7 + drug<br />
 
- 
-
}}
 
== References ==
== References ==
<references/>
<references/>
[[Category:Topic Page]]
[[Category:Topic Page]]

Revision as of 07:24, 8 September 2020

Human MAP2K1 complex with an anticancer agent, ATP and Mg+2 ion (PDB entry 3os3)

Drag the structure with the mouse to rotate

Mitogen-activated protein kinase kinase 3D structures

References

  1. ↑ Moscat J, Diaz-Meco MT, Albert A, Campuzano S. Cell signaling and function organized by PB1 domain interactions. Mol Cell. 2006 Sep 1;23(5):631-40. doi: 10.1016/j.molcel.2006.08.002. PMID:16949360 doi:http://dx.doi.org/10.1016/j.molcel.2006.08.002
  2. ↑ Weyman CM, Wolfman A. Mitogen-activated protein kinase kinase (MEK) activity is required for inhibition of skeletal muscle differentiation by insulin-like growth factor 1 or fibroblast growth factor 2. Endocrinology. 1998 Apr;139(4):1794-800. PMID:9528964 doi:http://dx.doi.org/10.1210/endo.139.4.5950
  3. ↑ Zheng CF, Guan KL. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem. 1993 Nov 15;268(32):23933-9. PMID:8226933
  4. ↑ Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):782-9. doi: 10.1016/S1470-2045(12)70269-3. Epub 2012, Jul 16. PMID:22805292 doi:http://dx.doi.org/10.1016/S1470-2045(12)70269-3
  5. ↑ Su GH, Song JJ, Repasky EA, Schutte M, Kern SE. Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat. 2002 Jan;19(1):81. PMID:11754110 doi:http://dx.doi.org/10.1002/humu.9002
  6. ↑ Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K, Miura T, Yoshimura Y, Aida S, Miwa M, Saitoh R, Murao N, Okabe H, Belunis C, Janson C, Lukacs C, Schuck V, Shimma N. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg Med Chem Lett. 2011 Jan 21. PMID:21316218 doi:10.1016/j.bmcl.2011.01.062

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman

Retrieved from "http://52.214.119.220/wiki/index.php/Mitogen-activated_protein_kinase_kinase"
Personal tools